EGFR and hypertensive disorder: The occurrence of specific AEs has been shown to predict better treatment responses both in target and endocrine therapy, such as rash induced by EGFR inhibitors [25, 26], hypertension after sunitinib treatment [27] and arthralgia/myalgia in exemestane treated patients [28].